Abraham Scaria
Company: Beacon Therapeutics
Job title: Chief Scientific Officer
Seminars:
Preclinical Updates for Complement Regulators Using Gene Therapies 2:00 pm
The benefits of using gene therapies to target complement mediated diseases Using a localised approach to target the eye and mitigate toxicity Updates in targeting Geographic Atrophy/Dry AMDRead more
day: Conference Day Two
Panel Discussion: Novel Modalities & Next Generation of Complement Inhibitors 3:30 pm
Where is the next step for complement inhibitors? Examine the past, present, and future, of complement inhibitors for autoimmune conditions and they may fit alongside existing therapiesRead more
day: End of Conference Day Two
Upstream vs. Downstream Targeting in GA & AMD 1:00 pm
Discussing the advantages and disadvantages of different complement targets through an ophthalmology lens Delivering complement inhibitors to the eye: topical, intravitreal, or systemic? Future considerations for combination therapies to target multiple complement components in the eyeRead more
day: Conference Day Two